142 related articles for article (PubMed ID: 24996052)
1. Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review.
Byers BA; Temple-Oberle CF; Hurdle V; McKinnon JG
J Surg Oncol; 2014 Nov; 110(6):770-5. PubMed ID: 24996052
[TBL] [Abstract][Full Text] [Related]
2. Intra-lesional interleukin-2 for the treatment of in-transit melanoma.
Boyd KU; Wehrli BM; Temple CL
J Surg Oncol; 2011 Dec; 104(7):711-7. PubMed ID: 21744347
[TBL] [Abstract][Full Text] [Related]
3. Intra-lesional interleukin-2 therapy for in transit melanoma.
Temple-Oberle CF; Byers BA; Hurdle V; Fyfe A; McKinnon JG
J Surg Oncol; 2014 Mar; 109(4):327-31. PubMed ID: 24453036
[TBL] [Abstract][Full Text] [Related]
4. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients.
Ridolfi L; Ridolfi R; Ascari-Raccagni A; Fabbri M; Casadei S; Gatti A; Trevisan G; Righini MG
J Eur Acad Dermatol Venereol; 2001 May; 15(3):218-23. PubMed ID: 11683284
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.
Radny P; Caroli UM; Bauer J; Paul T; Schlegel C; Eigentler TK; Weide B; Schwarz M; Garbe C
Br J Cancer; 2003 Nov; 89(9):1620-6. PubMed ID: 14583759
[TBL] [Abstract][Full Text] [Related]
6. Durability of Complete Response to Intralesional Interleukin-2 for In-Transit Melanoma.
Khoury S; Knapp GC; Fyfe A; Monzon J; Temple-Oberle C; McKinnon GJ
J Cutan Med Surg; 2021; 25(4):364-370. PubMed ID: 33529083
[TBL] [Abstract][Full Text] [Related]
7. [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2].
Dehesa LA; Vilar-Alejo J; Valerón-Almazán P; Carretero G
Actas Dermosifiliogr; 2009 Sep; 100(7):571-85. PubMed ID: 19715642
[TBL] [Abstract][Full Text] [Related]
8. Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease.
Hassan S; Petrella TM; Zhang T; Kamel-Reid S; Nordio F; Baccarelli A; Sade S; Naert K; Habeeb AA; Ghazarian D; Wright FC
Ann Surg Oncol; 2015; 22(6):1950-8. PubMed ID: 25366584
[TBL] [Abstract][Full Text] [Related]
9. Lesional therapies for in-transit melanoma.
Nadler A; Look Hong NJ; Alavi N; Abadir W; Wright FC
J Surg Oncol; 2020 Nov; 122(6):1050-1056. PubMed ID: 32668038
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD
Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875
[TBL] [Abstract][Full Text] [Related]
11. Locoregional therapies in melanoma.
Abbott AM; Zager JS
Surg Clin North Am; 2014 Oct; 94(5):1003-15, viii. PubMed ID: 25245964
[TBL] [Abstract][Full Text] [Related]
12. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.
Shi VY; Tran K; Patel F; Leventhal J; Konia T; Fung MA; Wilken R; Garcia MS; Fitzmaurice SD; Joo J; Monjazeb AM; Burrall BA; King B; Martinez S; Christensen SD; Maverakis E
J Am Acad Dermatol; 2015 Oct; 73(4):645-54. PubMed ID: 26259990
[TBL] [Abstract][Full Text] [Related]
13. The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma.
Beasley GM; Zager JS; Thompson JF
Ann Surg Oncol; 2020 Jan; 27(1):35-42. PubMed ID: 31471842
[TBL] [Abstract][Full Text] [Related]
14. [Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma].
Pföhler C; Steinhäuser S; Wagner A; Ugurel S; Tilgen W
Hautarzt; 2004 Feb; 55(2):171-5. PubMed ID: 14968328
[TBL] [Abstract][Full Text] [Related]
15. Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines.
Patel F; Wilken R; Burrall B; Martinez S; Wells V; King B; Maverakis E
Dermatol Online J; 2014 Nov; 20(11):. PubMed ID: 25419744
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Intra-Lesional Interleukin 2 for the Treatment of In-Transit Melanoma Disease: L'évaluation de l'interleukine-2 intralésionnelle pour traiter les mélanomes en transit.
Lopez-Obregon B; Barreto MP; Fyfe A; McKinnon G; Webb C; Temple-Oberle C
Plast Surg (Oakv); 2021 Feb; 29(1):4-9. PubMed ID: 33614534
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma.
Thompson JF; Agarwala SS; Smithers BM; Ross MI; Scoggins CR; Coventry BJ; Neuhaus SJ; Minor DR; Singer JM; Wachter EA
Ann Surg Oncol; 2015 Jul; 22(7):2135-42. PubMed ID: 25348780
[TBL] [Abstract][Full Text] [Related]
18. Intralesional PV-10 for in-transit melanoma-A single-center experience.
Lippey J; Bousounis R; Behrenbruch C; McKay B; Spillane J; Henderson MA; Speakman D; Gyorki DE
J Surg Oncol; 2016 Sep; 114(3):380-4. PubMed ID: 27237868
[TBL] [Abstract][Full Text] [Related]
19. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma.
Green DS; Dalgleish AG; Belonwu N; Fischer MD; Bodman-Smith MD
Br J Dermatol; 2008 Sep; 159(3):606-14. PubMed ID: 18616776
[TBL] [Abstract][Full Text] [Related]
20. In-transit melanoma: an individualized approach.
Grotz TE; Mansfield AS; Kottschade LA; Erickson LA; Otley CC; Markovic SN; Jakub JW
Oncology (Williston Park); 2011 Dec; 25(14):1340-8. PubMed ID: 22329185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
